«上一篇/Previous Article|本期目录/Table of Contents|下一篇/Next Article»

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:

2010年第3期

页码:

369-372

栏目:

临床研究

出版日期:

2010-04-06

文章信息/Info

Title:

Effect of combination of fuvastatin and felodipine on blood pressure, hs-CRP and vascular endothelial function in hypertensive patients with impaired glucose tolerance

作者:

鉴磊¹; 丛培玲²; 孙晓斐²; 张新岭²

1．山东省医学科学院，山东 济南 250062；2.济宁市第一人民医院心脏中心，山东 济宁 272100

Author(s):

JIAN Lei¹;  CONG Pei-ling²;  SUN Xiao-fei²;  ZHANG Xin-ling²

1.Shandong Academy of Medical Sciences, Jinan 250062, Shandong, China; 2.Department of Cardiology, Jining First People’s Hospital, Jining 272100, Shandong, China

关键词:

氟伐他汀; 非洛地平; 高血压; 原发性; 糖耐量减低; C反应蛋白; 内皮功能

Keywords:

fuvastatin;  felodipine;  hypertension;  impaired glucose tolerance;  C-reactive protein;  endothelium

分类号:

R972.4

DOI:

-

文献标识码:

A

摘要:

目的:观察在应用非洛地平的基础上加用氟伐他汀对糖耐量减低的高血压病患者超敏C反应蛋白（hs-CRP）及内皮功能的影响。方法: 将符合纳入标准的高血压病并发糖耐量减低的患者127例随机分为2组：对照组（n=66）和氟伐他汀组（n=61）,对照组服用非洛地平缓释片（10 mg，1次/d），氟伐他汀组在此基础上口服氟伐他汀（40 mg，1次/d），治疗12周。观察治疗前后患者hs-CRP和内皮功能等的变化。结果: 经12周治疗后，两组hs-CRP［对照组：(2.9±1.5)mg/L vs.(2.4±0.7)mg/L，P<0.05；氟伐他汀组：(2.9±1.5)mg/L vs.(1.3±0.4)mg/L，P<0.01］、可溶性细胞间黏附分子-1(sICAM-1)［对照组：(114±47)μg/L vs.(98±28)μg/L，P<0.05；氟伐他汀组：(118±46)μg/L vs.(78±24)μg/ml，P<0.01］及可溶性血管细胞黏附分子-1(sVCAM-1)［对照组：(2 265±99)μg/L vs.(190±56)μg/L，P<0.05；氟伐他汀组：(230±97)μg/L vs.(158±36)μg/L，P<0.01］水平明显下降，与对照组相比氟伐他汀组hs-CRP及SICAM-1、SVCAM-1有更明显的降低,比较差异有统计学意义(均P<0.01)。结论: 在应用非洛地平的基础上加用氟伐他汀能明显减低原发性高血压并发糖耐量减低患者hs-CRP的水平并改善患者的内皮功能。

Abstract:

AIM: To investigate the combined effects of fuvastatin and felodipine on blood pressure, hs-CRP and vascular endothelial function in hypertensive patients with impaired glucose tolerance (IGT). METHODS: One hundred and twenty seven patients with impaired glucose tolerance were randomized into two groups: treatment group and control group. Serum levels of soluble intercellular adhesion molecule-1 (sICAM-1), soluble vascular cell adhesion molecule-1 (sVCAM-1) and C-reactive protein (CRP) were measured before and after treatment. RESULTS: Twelve weeks after therapy, CRP levels ［control group: (2.9±1.5) mg/L vs.(2.4±0.7) mg/L, P<0.05; treatment group: (2.9±1.5) mg/L vs.(1.3±0.4) mg/L, P<0.01］, sICAM-1 ［control group: (114 ± 47) μg/L vs.( 98±28) μg/L, P<0.05; treatment group: (118±46) μg/L vs.(78±24) μg/L, P<0.01］ and sVCAM-1 ［control group: (226±99) μg/L vs.(190±56) μg/L, P<0.05; treatment group: (230±97) μg/L vs.(158±36) μg/L, P<0.01］ in the two groups significantly decreased. Compared with levels in the control group, the CRP levels ［(2.4±0.7)mg/L vs.(1.3±0.4)mg/L, P<0.05］; sICAM-1 ［(98±28)μg/L vs.(78±24)μg/L, P<0.05］ and sVCAM-1 ［(190±56)μg/L vs.(158±36)μg/L, P<0.05］ in the treatment group significantly decreased. CONCLUSION: Combination of fuvastatin and felodipine improves vascular endothelial-dependent diastolic function in hypertensive patients with impaired glucose tolerance by reducing plasma hs-CRP and blood glucose.

参考文献/References

［1］ Libby P, Aikawa M. Mechanisms of plaque stabilization with statins［J］. Am J Cardiol, 2003, 91(4A):4B-8B.

［2］Rider PM. High-sensitivity C-reactive protein: potential adjunct for global risk assess-ment in the primary prevention of cardiovascular disease［J］. Circulation, 2001, 103（13）:1813-1818.

［3］Adanopoulos S, Parissis J, Koupis C, et al. Physical training reduces peripheral marker of inflammation in patients with chronic heart failure［J］. Eur Heart J, 2001, 22（9）:791-797.

［4］Hinderliter AL, Caughey M. Assessing endothelial function as a risk factor for cardio-vascular disease［J］. Curr Atheroscler Rep, 2003, 5(6):506-513.

［5］都健,曾芙蓉,赵玉岩. 不同糖耐量水平者C反应蛋白与内皮功能的相关性研究［J］. 中华心血管病杂志, 2006, 34(5):443-444.

[6]Hayaishi-Okano R, Yamasaki Y, Katakami N, et al. Elevated Creactive protein associates with early-stage carotid atherosclerosis in young subjects with type 1 diabets［J］. Diabetes Care, 2002, 25(8):1432-1438.

[7]李建军.高血压可能是一种炎症相关性疾病［J］. 高血压病杂志, 2005, 13（6）：536-537.

[8]Halcox JP, Deanfield JE. Beyond the laboratory: clinical implications for statin pleiotropy［J］. Circulation, 2004, 109(21 Suppl 1):1142-1148.

[9] Horne BD, Muhlestein JB, Carlquist JF, et al. Intermountain Heart Collaborative (IHC) Study Group: statin therapy interacts with cytomegalovirus seropositivity and high C-reactive protein in reducing mortality among patients with angiographically significant coronary disease［J］. Circulation, 2003, 107（2）:258-263.

[10]Gupta S. Does aggressive statin therapy offer improved cholesterol-independent benefits compared to conventional statin treatment? ［J］. Int J Cardiol, 2004, 96（2）:131-139.

［11］ Bonetti PO, Lerman LO, Napoli C, et al. Statin effects beyond lipid lowering-are they clinically relevant?［J］. Eur Heart J, 2003 , 24（3）:225-248.

备注/Memo

备注/Memo:

收稿日期：2009-07-26.通讯作者：张新岭，主治医师，主要从事心力衰竭的临床与基础临床研究Email:xinling78@163.com 作者简介：鉴磊，硕士生Email:jianleiy@163.com

常用功能

更新日期/Last Update: 2010-04-09